FDA says COVID pill Paxlovid can be prescribed by pharmacists

The Food and Drug Administration (FDA) said Wednesday that it revised the emergency use authorization for Paxlovid, allowing authorized state-licensed pharmacists to prescribe the Pfizer antiviral medication to eligible patients.

“Since Paxlovid must be taken within five days after symptoms begin, authorizing state-licensed pharmacists to prescribe Paxlovid could expand access to timely treatment for some patients who are eligible to receive this drug for the treatment of COVID-19,” Dr. Patrizia Cavazzoni, director of the FDA’s Center for Drug Evaluation and Research, said in a statement.

There were “certain limitations” that would ensure patients were properly assessed and prescribed the drug.

State-licensed pharmacists should refer patients for clinical evaluation if sufficient information is not available to assess renal and hepatic function or to assess a potential drug interaction, the FDA said.

AMERICAN AIRLINES GLITCH LEAVES THOUSANDS OF FLIGHTS WITHOUT KEY CREW

COVID-19 treatment pill Paxlovid is seen in boxes at Misericordia hospital in Grosseto, Italy, on Feb. 8, 2022. (Reuters/Jennifer Lorenzini/Reuters)

The agency added that community pharmacies not already participating as test-to-treat sites can decide how or if they will offer this service.

Paxlovid is authorized for the treatment of mild-to-moderate COVID-19 infection in adults and pediatric patients with positive results of direct SARS-CoV-2 viral testing, who are at high risk for progression to severe COVID-19, including hospitalization or death.

It has been cleared for use and available for free in the US since December.

Pfizer's COVID pill

Paxlovid, Pfizer’s COVID-19 pill, is seen manufactured in Ascoli, Italy, in this undated handout photo obtained by Reuters on Nov. 16, 2021. (Pfizer/Handout via Reuters/Reuters)

GET FOX BUSINESS ON THE GO BY CLICKING HERE

Fewer than half of the nearly 4 million courses distributed to pharmacies by the government have been administered.

Those authorized who report a positive home test result from a rapid antigen diagnostic test or a positive PCR test, to their provider are eligible for the pill.

Patients who test positive should bring health records for pharmacists to review for kidney and liver problems.

Anti-viral COVID medication Paxlovid

Paxlovid, Pfizer’s antiviral medication to treat COVID-19, is displayed in this picture illustration taken in Medford, Massachusetts, on May 12, 2022. (Reuters/Brian Snyder/Illustration/File Photo/Reuters)

CLICK HERE TO READ MORE ON FOX BUSINESS

Patients with reduced kidney function may need a lower dose of the treatment.

Reuters contributed to this report.

Leave a Comment

Your email address will not be published.